Lymphoma: The Bête Noire of the long-term use of thiopurines in adult and elderly patients with inflammatory bowel disease

Gastroenterology

Volumn 145, Issue 5, 2013, Pages 927-930

  Beaugerie, Laurent ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MERCAPTOPURINE; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGE; AGED; ANTIVIRAL THERAPY; BASAL CELL CARCINOMA; CANCER RISK; CHICKENPOX; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; ENTERITIS; EPSTEIN BARR VIRUS INFECTION; GENDER; HEMOPHAGOCYTIC SYNDROME; HEPATOSPLENIC T CELL LYMPHOMA; HIGH RISK PATIENT; HUMAN; INTESTINE LYMPHOMA; LYMPHOMA; NON MELANOMA SKIN CANCER; POSTTRANSPLANT LYMPHOMA; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION;

EID: 84886789606     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2013.09.035     Document Type: Editorial

References (21)

1. N. Khan, A.M. Abbas, and G.R. Lichtenstein Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study Gastroenterology 145 2013 1007 1015
2. L. Beaugerie, N. Brousse, and A.M. Bouvier Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study Lancet 374 2009 1617 1625
3. L. Beaugerie, M. Svrcek, and P. Seksik Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease Gastroenterology 145 2013 166 175.e8
4. M.D. Long, C.F. Martin, and C.A. Pipkin Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease Gastroenterology 143 2012 390 399.e1
5. G.R. Lichtenstein, B.G. Feagan, and R.D. Cohen Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry Clin Gastroenterol Hepatol 4 2006 621 630
6. L. Beaugerie Inflammatory bowel disease therapies and cancer risk: where are we and where are we going? Gut 61 2012 476 483
7. V.F. Biank, M.K. Sheth, and J. Talano Association of Crohn's disease, thiopurines, and primary Epstein-Barr virus infection with hemophagocytic lymphohistiocytosis J Pediatr 159 2011 808 812
8. M. Toruner, E.V. Loftus Jr., and W.S. Harmsen Risk factors for opportunistic infections in patients with inflammatory bowel disease Gastroenterology 134 2008 929 936
9. L. Peyrin-Biroulet, K. Khosrotehrani, and F. Carrat Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease Gastroenterology 141 2011 1621 1628.e5
10. E. Roman, and A.G. Smith Epidemiology of lymphomas Histopathology 58 2011 4 14
11. D.S. Kotlyar, M.T. Osterman, and R.H. Diamond A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease Clin Gastroenterol Hepatol 9 2011 36 41
12. G.A. Dayharsh, E.V. Loftus Jr., and W.J. Sandborn Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine Gastroenterology 122 2002 72 77
13. F. Pietersma, E. Piriou, and D. van Baarle Immune surveillance of EBV-infected B cells and the development of non-Hodgkin lymphomas in immunocompromised patients Leuk Lymphoma 49 2008 1028 1041
14. G. Opelz, and B. Dohler Lymphomas after solid organ transplantation: a collaborative transplant study report Am J Transplant 4 2004 222 230
15. H. Sokol, L. Beaugerie, and M. Maynadie Excess intestinal lymphoproliferative disorders in IBD Inflamm Bowel Dis 18 2012 2063 2071
16. S. Kumar, F. Fend, and L. Quintanilla-Martinez Epstein-Barr virus-positive primary gastrointestinal Hodgkin's disease: association with inflammatory bowel disease and immunosuppression Am J Surg Pathol 24 2000 66 73
17. J.D. Lewis, J.S. Schwartz, and G.R. Lichtenstein Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma Gastroenterology 118 2000 1018 1024
18. M. Lemann, J.Y. Mary, and J.F. Colombel A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine Gastroenterology 128 2005 1812 1818
19. E. Louis, J.Y. Mary, and G. Vernier-Massouille Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped Gastroenterology 142 2012 63 70.e5 quiz e31
20. N. De Suray, G. Vernier-Massouille, and J.C. Grimaud Close monitoring of CRP and fecal calprotectin is able to predict clinical relapse in patients with Crohn's disease in remission after infliximab withdrawal. A sub-analysis of the Stori study Gastroenterology 142 2010 S-149
21. F.R. Johnson, S. Ozdemir, and C. Mansfield Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy Gastroenterology 133 2007 769 779